RxDoctor Payments Data

Rita Dhawan, MD

Family Medicine · Pasadena, MDNPI 1134120793

Payments from drug & device makers

$923in general payments, 2019–2025

Across 26 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$248
  • Urovant Sciences Inc$123
  • Eisai Inc.$121
  • Aimmune Therapeutics, Inc.$86
  • Sunovion Pharmaceuticals Inc.$81
  • Amgen$79
  • plus $187 from 9 others

What the payments were for

  • Food & beverage$89497%
  • Education$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$121,187
Medicare patients
293
Services billed
1,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$98,881
Humira(Cf)Adalimumab12$76,914
EntrestoSacubitril/Valsartan18$15,048
SantylCollagenase Clostridium Hist.12$14,034
JardianceEmpagliflozin26$13,875
XareltoRivaroxaban24$10,485
MyrbetriqMirabegron26$10,236
JanuviaSitagliptin Phosphate38$10,216
Memantine Hcl122$7,427
Atorvastatin Calcium418$7,035
Sevelamer Carbonate16$6,010
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$4,912
Potassium Chloride146$4,315
Mirtazapine128$3,546
Levothyroxine Sodium266$3,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$15$101,740211 claims
AbbVieHumira(Cf), Synthroid$25$79,11836 claims
NovartisEntresto$21$15,04818 claims
Johnson & JohnsonXarelto$248$10,48524 claims
Astellas Pharma US IncMyrbetriq$15$10,23626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →